Calpain is hyperactivated in human failing hearts and rodent heart failure models of different etiologies.
SUMMARY
Heart failure remains a major cause of morbidity and mortality in developed countries. There is still a strong need to devise new mechanism-based treatments for heart failure. Numerous studies have suggested the importance of the Ca 2þ -dependent protease calpain in cardiac physiology and pathology.
However, no drugs are currently under development or testing in human patients to target calpain for heart failure treatment. Herein the data demonstrate that inhibition of calpain activity protects against deleterious ultrastructural remodeling and cardiac dysfunction in multiple rodent models of heart failure, providing compelling evidence that calpain inhibition is a promising therapeutic strategy for heart failure (4, 5) . Calpain activation has been implicated in pathogenesis of myocardial remodeling and heart failure (6) . Using an inducible cardiac-specific overexpression mouse model system, the Dorn group demonstrated that exogenous overexpression of calpain-1, but not calpain-2, in vivo results in heart failure and early mortality (7) . Conversely, genetic inhibition of calpain activity reduces myocardial injury and improves cardiac function in mice post-MI (8).
However, limited studies have explored use of pharmacological calpain inhibitors as a therapeutic strategy for antagonizing heart failure development or progression.
In the present study, we tested the therapeutic efficacy of pharmacological calpain inhibition in multiple animal models of heart failure. Due to the diversity of calpain substrates and the known function of calpain-mediated JP2 proteolysis, we then examined the specific contribution of JP2 cleavage in have reported that they have no relationships relevant to the contents of this paper to disclose.
calpain-mediated cardiac remodeling and dysfunction using calpain-1 and JP2 double-transgenic mice.
Our study provides proof-of-concept evidence that inhibition of calpain activity is a potential strategy for the treatment of heart failure. at the University of Iowa. Chronic heart failure models were established using male C57BL/6N mice (9 to 10 weeks of age). Cardiac-specific, inducible calpain-1 overexpressing mice (CAPN1-OE) (7), (obtained from the Jackson Laboratory, Bar Harbor, Maine) and JP2 overexpressing mice (JP2-OE) (both on a C57BL/6N background) (9) were crossed to generate double-transgenic mice (CAPN1-OExJP2-OE mice). Briefly, both overexpression mouse models were made using modified aMHC promoter which contains the tet-operon (tet-off) (see Figure 1A of Guo et al. [9] ). Each transgenic mouse strain was crossed first with aMHC-tTA to generate tTA-CAPN1 mice or tTA-JP2 mice. These 2 strains of mice were then crossed to generate CAPN1-OExJP2-OE doubletransgenic mice (controlled by aMHC-tTA). The expression of transgenes (CAPN1 and/or JP2) can be turned off by adding doxycycline to chow (625 mg/kg) and turned on by ceasing doxycycline feeding. Here, in the present study, the mice were studied in the absence of doxycycline. In other words, calpain and/ or JP2 overexpression occurs since embryonic stage.
METHODS
Either sex of the transgenic mice and wild-type littermates was used for experiments.
MOUSE MODELS OF HEART FAILURE. Chronic heart failure was modeled in male C57BL/6N mice at 9 to 10 weeks of age using 3 different methods: 1) MI surgery by suturing the left anterior descending branch of the coronary artery as previously described (10) Transthoracic echocardiograms were performed at the University of Iowa Cardiology Animal Phenotyping Core Laboratory using a Vevo 2100 Imager (VisualSonics, Toronto, Ontario, Canada) as previously described (9, 10) . After completion of 2-dimensional imaging, the animals were euthanized, and both the heart and lungs were dissected and weighed.
IN SITU TRANSVERSE TUBULE AND CA 2 D IMAGING.
Confocal imaging of transverse tubules (T-tubules)
and Ca 2þ handling in Langendorff-perfused intact hearts were performed as described previously (11, 12) .
The strength of regularity of T-tubules (TT power ) was analyzed using AutoTT custom software (13) . Analyses of Ca 2þ transients were performed as previously described (14) .
WESTERN BLOT ANALYSIS. Western blotting was performed as described previously (15) .
CALPAIN ACTIVITY ASSAY. Calpain activity in heart lysates was determined using a calpain activity assay kit (ab65308, Abcam, Cambridge, Massachusetts), according to the manufacturer's protocol. Heart lysates were obtained from mice treated with MDL-28170 or saline for 5 weeks since day 3 after surgery.
Twenty-four h after last injection of MDL-28170, mice were subjected to echocardiography, and then hearts were collected for histology, biochemical, or enzyme activity assays. 
RESULTS

CALPAIN ACTIVITY IS INCREASED IN END-STAGE
HEART FAILURE PATIENTS. To determine the relationship between calpain activity and cardiac structure and function in human heart failure, we examined calpain activity and protein expression levels in LV lysates from end-stage heart failure patients with ischemic cardiomyopathy or dilated cardiomyopathy. As compared with healthy donor hearts, calpain activity and calpain-1 expression were significantly increased in failing hearts of both etiologies ( Figures 1A to 1C ). By contrast, the expression level of calpastatin, an endogenous calpain inhibitor,
was not altered in diseased heart samples ( Figure 1D ). Wang et al.
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Calpain proteolytically cleaves a number of cardiac proteins with known roles in cardiac homeostasis.
For example, our group demonstrated that JP2, a membrane-binding protein that provides a structural bridge between the plasmalemma and SR, is a direct substrate of calpain in cardiomyocytes (16) . JP2 downregulation is involved in the progression of heart failure in multiple animal models of cardiac stress (16, 17) . Analysis of JP2 protein levels in failing human hearts revealed a marked w45% reduction in both ischemic cardiomyopathy and dilated cardiomyopathy samples as compared with healthy myocardium ( Figures 1B and 1E) . As a control, we also observed a significant increase of cleaved a-Fodrin, a typical calpain substrate, in human failing hearts ( Figure 1F ).
CALPAIN INHIBITOR PRESERVES CARDIAC FUNCTION AFTER CARDIAC STRESS.
To investigate the impact of calpain inhibition on cardiac structure and function in chronic heart failure, we utilized 3 common animal models of heart failure: MI, pressure overload via TAB, and ISO minipump infusion. To assess the efficacy of calpain inhibition as a therapeutic modality, mice were treated with the calpain inhibitor MDL-28170 (10 mg/kg/day, IP), a cell-penetrating di-peptidyl aldehyde inhibitor, beginning at 3 days after surgery or implantation of the ISO minipump.
We first established that, as expected, calpain activity is increased in all models of heart failure as Together, these data suggest that elevated calpain activity is a general mechanism for cardiac dysfunction and pathological remodeling induced by cardiac stress, and inhibition of calpain after injury is protective.
In another set of experiments, we further tested whether inhibiting calpain activity will be still effective in TAB mice with established cardiac dysfunction. MDL-28170 was administered beginning at 3 weeks following TAB and continued for 3 weeks (10 mg/kg/day, IP). The EF of TAB mice without MDL-28170 treatment were decreased by 44% during this period, whereas the EF of the MDL-28170 treatment group was reduced by only 18% (Supplemental Figure S3 ). Taken together, these data suggest that inhibiting calpain activity represents an effective strategy in mitigating the development and progression of heart failure. Wang et al.
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function, at least partially, by preserving JP2 expression and T-tubule structural integrity. system; other abbreviations as in Figure 2 .
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Inhibiting Calpain Activity to Treat Heart Failure the relative role of calpain-dependent cleavage of JP2 in heart failure mediated by excessive calpain activation. To test this, we examined transgenic mice with cardiac-specific overexpression of calpain-1 alone (CAPN1-OE mice) or with dual overexpression of calpain-1 and JP2 (CAPN1-OExJP2-OE mice), which were generated by crossing CAPN1-OE mice with JP2-OE mice. Expression of the transgene was increased by w3-fold in both CAPN1-OE mice and JP2-OE mice (Supplemental Figures S5 and S6 ).
We first asked whether JP2 overexpression can protect against the deleterious effects of calpain-1 overexpression. As compared with wild-type (WT) mice, the overall 2-and 3-week relative survival rates of CAPN1-OE mice were 92% and 76%, respectively, whereas the corresponding survival rates for CAPN1-OExJP2-OE mice were higher, with w100% at 2 and 3 weeks. The double-transgenic mice started to die at day 25. However, beginning at 4 weeks of age, the relative survival rates were nearly identical between the CAPN1-OE and CAPN1-OExJP2-OE groups (72% to 75%). The Kaplan-Meier survival curves continued to overlap between groups at 5 weeks (w58%) ( Figure 5A ). These data indicate that JP2 overexpression delayed the onset of cardiac sudden death and thus initially prolonged survival, but was not sufficient to protect against the adverse effects of sustained calpain-1 overactivation.
In line with the survival data, CAPN1-OE mice had significantly decreased LVEF beginning at 3 weeks of age as compared with WT mice ( Figure 5B ). Dual expression of calpain and JP2 attenuated this decrease at 3 weeks, but the protection was lost beginning at 4 weeks. Similarly, end-diastolic volume and end-systolic volume were significantly improved and heart weight/body weight and lung weight/body weight ratios were decreased in the CAPN1-OExJP2-OE mice at 3 weeks, but not at later ages, as compared with CAPN1-OE mice ( Figures 5C to 5F ).
These results indicate that JP2 overexpression in the setting of sustained calpain-1 overexpression is not sufficient to mitigate spontaneous heart failure. Wang et al.
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JP2 EXPRESSION PROGRESSIVELY DECLINES IN
CAPN1-OExJP2-OE MICE. To understand the underlying mechanism of the aforementioned findings, we first examined the impact of JP2 overexpression on calpain activity. CAPN1-OE mice had a 1.8-fold increase in calpain activity in the heart at 2 weeks after birth as compared with WT mice ( Figure 6A ).
Calpain activity progressively increased between 2 and 5 weeks after birth, with a 2.2-fold increase in calpain activity at 5 weeks. In CAPN1-OExJP2-OE mice, calpain activity was nearly identical to that observed in CAPN1-OE mice at all time points examined ( Figure 6A ), demonstrating that cooverexpression of JP2 does not alter calpain function.
We next investigated whether JP2 expression is sustained or down-regulated in CAPN1-OExJP2-OE mice. As expected, JP2 levels in CAPN1-OE mice progressively decreased with age as compared with WT controls (Figures 6B and 6C) . At 2 weeks after birth, JP2 levels in CAPN1-OExJP2-OE mice were 1.2-fold higher than in WT mice. By 3 weeks of age, however, JP2 levels were trending toward a decrease in CAPN1-OExJP2-OE mice as compared with WT mice. JP2 levels continued to decline with age in CAPN1-OExJP2-OE mice, with levels nearly identical to CAPN1-OE mice at 5 weeks ( Figures 6B and 6C) . These results indicate that JP2 overexpression is not sufficient to antagonize the deleterious effects of calpain overexpression. 
JP2-OE INITIALLY PRESERVES T-TUBULE
Calpain activity assay in heart lysates from WT, CAPN1-OE, and CAPN1-OExJP2-OE mice at different ages. (B, C) Representative Western blot (B) and summary data (C) of JP2 expression in heart lysates WT, CAPN1-OE, and CAPN1-OExJP2-OE mice. n ¼ 6 to 11 per group. *p < 0.05, **p < 0.01 versus age-matched WT; †p < 0.05, † †p < 0.01 versus age-matched CAPN1-OE. Abbreviations as in Figure 5 . 
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DISCUSSION
Abundant evidence demonstrates that calpains target many proteins that are required for cardiac homeostasis, and calpain activity is markedly enhanced in multiple heart failure models (3, 6) .
Despite this resounding evidence, no clinical studies have pursued calpain inhibition as a therapeutic opportunity for heart failure. In this study, we first established that calpain is hyperactive in human failing hearts of different etiologies and in 3 different rodent models of heart failure. Second, we observed Our data substantiate previous reports of the protective role of calpain inhibition in cardiomyopathies.
For example, transgenic overexpression of the Recent work from our group established that JP2, a structural protein spanning T-tubules and the SR membrane, is crucial for maintaining normal T-tubule organization (9, 11, 32) . Our previous data on animal models of cardiac stress show that down-regulation of the JP2 is associated with T-tubule disorganization and heart failure development (11), whereas overexpression of JP2 protects against stress-induced heart failure and sudden cardiac death (9) . We also found that JP2 down-regulation is driven by activation of the Ca 2þ -dependent protease, calpain (16, 17) . 
CONCLUSIONS
Our data demonstrate that hyperactivation of the calpain proteolytic system leads to heart failure in part through JP2 down-regulation and T-tubule remodeling, and these harmful effects can be pre- 
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Classical heart failure treatments, in particular angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and beta-blockers, have been shown to improve heart function, prolong life, and reduce heart failure-associated sudden cardiac death. However, there is still a strong need to devise new mechanism-based treatments for heart failure.
TRANSLATION OUTLOOK: Inhibiting calpain activity is a promising therapeutic strategy for heart failure treatment by mitigating cardiac remodeling and the progression of heart failure. When combined with other heart failure medications, calpain inhibitor may exert synergistic effects on protection of cardiac structure and function, and on prolongation of patient lifespan.
